Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HB-201 |
Synonyms | |
Therapy Description |
HB-201 consists of lymphocytic choriomeningitis virus that is engineered to express an HPV16-derived E6/E7 fusion protein, which potentially induces host immune response, thereby resulting in the lysis of HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HB-201 | HB201|HB 201|HPV E6/E7-encoding arenavirus vaccine HB-201 | HB-201 consists of lymphocytic choriomeningitis virus that is engineered to express an HPV16-derived E6/E7 fusion protein, which potentially induces host immune response, thereby resulting in the lysis of HPV16 E6 and E7-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04180215 | Phase Ib/II | HB-201 + HB-202 HB-201 + Nivolumab HB-201 HB-201 + HB-202 + Nivolumab | A Study of TheraT Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers | Recruiting | USA | NLD | ESP | 0 |
NCT04630353 | Phase I | HB-201 | A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer | Terminated | USA | 0 |